ArticleJAAD international2021
Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis.
Article in JAAD international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Role of real-world evidence from patient registries for psoriasis in decision-making: a systematic review.BMJ open quality · 2026Pooled it
- Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life.Dermatology and therapy · 2025Article
- Predictors of treatment survival in patients with plaque psoriasis treated with phototherapy: registry analysis.Skin health and disease · 2025Article
- Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology.Pharmaceutics · 2025Review
- Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients.Frontiers in immunology · 2025Observational
- Psoriasis and its impact on close relatives and partners of patients - A cross-sectional questionnaire study.Skin health and disease · 2024Article
- Gender perspective in psoriasis: a scoping review and proposal of strategies for improved clinical practice by European dermatologists.International journal of women's dermatology · 2023Article
- Early Discontinuation of Apremilast in Patients with Psoriasis and Gastrointestinal Comorbidities: Rates and Associated Risk Factors.Dermatology and therapy · 2023Article
- Atopic Dermatitis and Water: Is There an Optimum Water Intake Level for Improving Atopic Skin?Children (Basel, Switzerland) · 2023Review
- Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis.Biologics : targets & therapy · 2023Article
- Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria - results the APPRECIATE study.Therapeutic advances in chronic disease · 2023Article
- Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA).Scientific reports · 2022Observational
- Article
- The Link Between Obesity and the Skin.Frontiers in nutrition · 2022Review
Corrections and comments
- Erratum issuedCorrection.2021
Authors and funding
28 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about the effectiveness and drug survival associated with apremilast under real-world conditions.
objectiveTo investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard to the psoriasis area and severity index (PASI) reduction.
methodsThis was an observational, retrospective, multicenter analysis from the Austrian Psoriasis Registry.
resultsData from 367 patients were eligible for analysis. The 12-month drug survival rate associated with apremilast (ie, the proportion of patients on the drug) was 57.3% and decreased significantly in patients younger than 40 years (relative hazard ratio = 1.49, LIMITATIONS: Inclusion of a substantial number of patients with no record of absolute PASI at study entry and lack of PASI reduction follow-up data of 103 patients (28.1%) after starting apremilast treatment.
conclusionApremilast is a robust antipsoriatic drug for which the drug survival is not strongly influenced by most patient- or disease-related factors except age. Drug survival is significantly shorter in patients younger than 40 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.